Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Ellard, Susan L., Clemons, Mark, Gelmon, Karen A., Norris, Brian, Kennecke, Hagen, Chia, Stephen, Pritchard, Kathleen, Eisen, Andrea, Vandenberg, Ted, Taylor, Marianne, Sauerbrei, Eric, Mishaeli, Moshe, Huntsman, David, Walsh, Wendy, Olivo, Martin, McIntosh, Lynn, Seymour, Lesley·2009·Journal of Clinical Oncology

Abstract

Purpose: To evaluate the safety and efficacy of oral everolimus, a mammalian target of rapamycin (mTOR) inhibitor, in two different schedules in minimally pretreated patients with metastatic breast cancer and to explore for possible biologic correlates of response. Patients and Methods: Patients who received no or one prior chemotherapy regimen for metastatic breast cancer were entered onto this multicenter, noncomparative, randomized phase II study of everolimus 10 mg daily versus 70 mg weekly; the multinomial end points of response and progression were evaluated at 8 weeks. A two-stage accrual design was used, with 15 evaluable patients in each schedule in stage 1. Only daily therapy met criteria for continuing, and another 15 patients were added. pAKT, PTEN, carbonic anhydrase 9, estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) were evaluated for possible correlation with response. Results: The most common drug-related toxicities were fatigue, rash, anorexia, diarrhea, stomatitis, cough, and pneumonitis. Pneumonitis occurred at higher than expected rates and seemed to be schedule dependent, with the highest incidence on the daily schedule. Response rate with daily therapy was 12% (95% CI, 3.4% to 28.2%) compared with 0% (95% CI, 0.0% to 20.6%) for weekly therapy. Twenty-seven percent of patients on daily therapy discontinued treatment compared with 13% on weekly therapy (16% v 6% with pneumonitis, respectively). No biologic correlates of response could be identified, although there were trends favoring benefit in ER-positive and HER2-negative metastatic breast cancer. Conclusion: Oral everolimus has activity in metastatic breast cancer that is schedule dependent. Daily therapy with 10 mg is worthy of further study in this patient population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.21.3033

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 258

Metadata

Authors
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., Sauerbrei, E., Mishaeli, M., Huntsman, D., Walsh, W., Olivo, M., McIntosh, L., & Seymour, L.
Venue
Journal of Clinical Oncology
Published
2009-09-20
Volume
27
Issue
27
Pages
4536-4541
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2121917721
Cited by
258
References
2
FWCI
23.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163. https://app.cochat.ai/papers/10.1200/jco.2008.21.3033
The paper
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., Sauerbrei, E., Mishaeli, M., Huntsman, D., Walsh, W., Olivo, M., McIntosh, L., & Seymour, L. (2009). Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.21.3033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.